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I)
Synthesis and mass spectrum of 3,4,-ethylenedioxyphenyl-2-palmitoylamino-3-
pyrrolidino-1-propanol (EtDO-P4).
The EtDO-P4 was synthesized as described by Lee et al. (1999) . Its identity was confirmed by mass spectrometry (Fig. S1 ). Figure S1 . ESI-MS spectrum of 3,4,-ethylenedioxyphenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (EtDO-P4).
II) HPLC purification of EtDO-P4 stereoisomers.
The D-threo-1-(3,4,-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, DEtDO-P4, the active stereoisomer of EtDO-P4, was purified by HPLC on a chiral column under conditions described by Lee et al. (1999) . 
III) D-EtDO-P4 and D-PDMP decrease GM3 ganglioside level in HepG2 cells in a concentration and time dependent manner.
After 96 h of incubation cell with decreasing concentration of D-EtDO-P4 or D-PDMP we observed a reduction to about 35% (30.2% -42%, n=3) for 40 µM D-PDMP (Fig. 3A) and a similar decrease of GM3 for D-EtDO-P4 was recorded at about 0.1 µM to 1 µM concentration of the inhibitor (Fig. 3B) . 
